Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Jun 23, 2025
- Pharmaceuticals
- R&D
Roche Announces Global Phase III SUNMO Study Data for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Combination Therapy with Lunsumio and Polivy)
TOKYO, June 23, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a news release on June 20th regarding the data presentation of the Global Phase III SUNMO study for relapsed/refractory diffuse large B-cell lymphoma at the 18th International Conference on Malignant Lymphoma (ICML).
The study demonstrated a statistically significant and clinically meaningful improvement in its primary endpoints of progression-free survival (PFS) and objective response rate (ORR). The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines.
Please refer to the link below for details of the news release:
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
https://www.roche.com/media/releases/med-cor-2025-06-20
Trademarks used or mentioned in this release are protected by laws.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp